Aurobindo Pharma Ltd NSE  /  BSE

Pharmaceuticals, Large Cap

19 Jul 2019 | 04:14 PM

552.40
-17.50 (-3.07%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts positive since 12-Feb-2019

    Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 12-Feb-2019 at a price of 767.90.

  • Valuation Rating

    Strongly undervalued

    Based on its growth potential and our own criteria, at its current price the stock is strongly undervalued.

  • MT Tech Trend

    Trend positive since 12-Mar-2019

    The forty day Medium Term Technical Trend is positive since 12-Mar-2019. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 739.621.

  • 4W REL Performance

    vs. SENSEX30

    The four week relative overperformance versus SENSEX30 is 2.430.

Risk parameters

  • Risk Zone

    Moderate

    The stock has been on the moderate-sensitivity level since 03-Aug-2018.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 246%.

  • Beta

    111 High sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 111%.

  • Correlation

    0.39 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.99.14 The medium term value at risk is estimated at 99.14 or 0.12679%

    The value at risk is estimated at 99.14. The risk is therefore 0.12679%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    19.57 Current year to 2020 annualized estimate

    The annualized growth estimate is for the current year to 2020.

  • P/E Ratio

    13.11 Estimated PE for 2020

    The estimated PE is for the year 2020.

  • G/PE Ratio

    1.53 >40% discount to expected growth

    A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio higher than 1.5 indicates that the stock's price presents a discount to growth >40% in this case.

  • Dividend Yield

    0.49% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 6.374% of earnings forecasts.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 26-Mar-2019.